395 related articles for article (PubMed ID: 16972901)
1. Immune resistance orchestrated by the tumor microenvironment.
Gajewski TF; Meng Y; Blank C; Brown I; Kacha A; Kline J; Harlin H
Immunol Rev; 2006 Oct; 213():131-45. PubMed ID: 16972901
[TBL] [Abstract][Full Text] [Related]
2. Immune suppression in the tumor microenvironment.
Gajewski TF; Meng Y; Harlin H
J Immunother; 2006; 29(3):233-40. PubMed ID: 16699366
[TBL] [Abstract][Full Text] [Related]
3. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
[TBL] [Abstract][Full Text] [Related]
4. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2326s-2330s. PubMed ID: 16609053
[TBL] [Abstract][Full Text] [Related]
5. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
Poggi A; Zocchi MR
Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
[TBL] [Abstract][Full Text] [Related]
7. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
Neeson P; Paterson Y
Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
9. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
Gajewski TF
Curr Opin Investig Drugs; 2004 Dec; 5(12):1279-83. PubMed ID: 15648949
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer.
Gross S; Walden P
Immunol Lett; 2008 Feb; 116(1):7-14. PubMed ID: 18164076
[TBL] [Abstract][Full Text] [Related]
11. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
12. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
13. Tumor-driven evolution of immunosuppressive networks during malignant progression.
Kim R; Emi M; Tanabe K; Arihiro K
Cancer Res; 2006 Jun; 66(11):5527-36. PubMed ID: 16740684
[TBL] [Abstract][Full Text] [Related]
14. Metabolic mechanisms of cancer-induced inhibition of immune responses.
Viola A; Bronte V
Semin Cancer Biol; 2007 Aug; 17(4):309-16. PubMed ID: 17651985
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous autoimmunity sufficiently potent to induce diabetes mellitus is insufficient to protect against insulinoma.
Zwicker K; Chatten C; Gratton K; Demetrick D; Serra P; Shameli A; Santamaria P; Bathe OF
J Immunol; 2009 Aug; 183(3):1705-14. PubMed ID: 19570832
[TBL] [Abstract][Full Text] [Related]
16. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines.
Gross S; Geldmacher A; Sharav T; Losch F; Walden P
Vaccine; 2009 May; 27(25-26):3398-400. PubMed ID: 19200836
[TBL] [Abstract][Full Text] [Related]
18. Breaking tolerance in cancer immunotherapy: time to ACT.
Overwijk WW
Curr Opin Immunol; 2005 Apr; 17(2):187-94. PubMed ID: 15766680
[TBL] [Abstract][Full Text] [Related]
19. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
Valenti R; Huber V; Filipazzi P; Pilla L; Sovena G; Villa A; Corbelli A; Fais S; Parmiani G; Rivoltini L
Cancer Res; 2006 Sep; 66(18):9290-8. PubMed ID: 16982774
[TBL] [Abstract][Full Text] [Related]
20. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
